- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Medicare weight loss drug pilot on ice as insurers decline to contribute | ||
| 14:46 | MSD-backed Ray locks in $125m to back eye drug pipeline | ||
| 13:46 | FDA approves MSD's once-daily HIV combo Idvynso | ||
| 11:46 | BioAegis and Prenosis partner for inflammatory disease therapies | ||
| 09:46 | Health Canada approves Biocon's two denosumab biosimilars | ||
| Di | Eli Lilly doubles down on in vivo with $7bn Kelonia buyout | ||
| Di | Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy | ||
| Di | Asahi Kasei acquires German company Aicuris | ||
| Mo | British patients risking "fake" weight loss drugs, despite safety concerns, survey says | ||
| Mo | Boehringer Ingelheim launches AI centre in London | ||
| Mo | Trump backs psychedelics for mental health in new executive order | ||
| Mo | UCB to purchase Neurona and NRTX-1001 for $1.15bn | ||
| Mo | MSD secures EC approval for Enflonsia to prevent infant RSV infection | ||
| Fr | Kailera makes history with record-breaking $625m IPO | ||
| Fr | Aligos and Xiamen Amoytop sign deal for HBV therapy | ||
| Fr | Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions | ||
| Do | Developers back Alzheimer's drugs despite report suggesting lack of efficacy | ||
| Do | Lilly debuts more Foundayo data as FDA requests post-marketing trials | ||
| Do | Terremoto wins $108m in Series C to drive cancer and rare disease programmes | ||
| Do | Nucleai and Sirona Dx to provide new proteomics solution for pharma companies | ||
| Do | Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study | ||
| 15.04. | FDA shares guide on genome editing best practices | ||
| 15.04. | Amazon launches AI drug discovery platform | ||
| 15.04. | J&J sets the tone for Q1 earnings with strong oncology growth | ||
| 15.04. | Adcendo secures $75m in Series C funding for ADC development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.